Karyopharm Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Karyopharm Therapeutics's estimated annual revenue is currently $30.3M per year.
- Karyopharm Therapeutics received $Undisclosed in venture funding in January 2015.
- Karyopharm Therapeutics's estimated revenue per employee is $78,795
- Karyopharm Therapeutics's total funding is $178.3M.
- Karyopharm Therapeutics has 385 Employees.
- Karyopharm Therapeutics grew their employee count by 50% last year.
- Karyopharm Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Vita Data Scien...||$10.3M||51||50%||N/A||N/A|
What Is Karyopharm Therapeutics?
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. For more information, please visit www.karyopharm.comkeywords:Biotechnology,Cleantech,Healthcare,Marketing,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Amnon Eylath||Associate Vice President & Quality Head|
|Borah Kaabunga||Manager, Site Payments|
|Michael Mason||Chief Financial Officer|
|Sharon Shacham||Founder||Email Available|
|Brian Austad||Senior Vice President And Head Of Pharmaceutical Sciences||Email Available|
|Shijie Tang||Executive Director, Head Of Biostatistics||Email Available|
|Jatin Shah||Svp Clinical Development|
|Sharon Tamir||Director, Strategic Product Development, Head of Neurodegenerative and Infectious Diseases||Email Available|
|William Senapedis||Director||Email Available|
|Wen Chen||Senior Director Of Pharmaceutical Sciences, Formulation Development||Email Available|
Karyopharm Therapeutics News
NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc.
13, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that ...
Michael Kauffman became the CEO of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in 2011. This analysis aims first to contrast CEO ...
Karyopharm Therapeutics Funding
|2015-01-07||$Undisclosed||Undisclosed||BofA Merrill Lynch||Article|
Karyopharm Therapeutics Executive Hires
|2014-04-11||Christopher B. Primiano||VP General Counsel/Secretary||Article|
|2016-09-13||Humphrey A.R. Gardner||SVP Clinical Development||Article|
|2017-09-13||Michael Falvey||evp/Chief Financial Officer/Treasurer||Article|
|2018-06-26||Anand Varadan||EVP Chief Commercial Officer||Article|